NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS
Version 2 2024-06-05, 11:39Version 2 2024-06-05, 11:39
Version 1 2021-05-11, 15:32Version 1 2021-05-11, 15:32
conference contribution
posted on 2024-06-05, 11:39authored byG Paul Amminger, Barnaby Nelson, Hok Pan Yuen, Connie Markulev, Miriam R Schaefer, Monika Schloegelhofer, Nilufar Mossaheb, Stephan Smesny, Ian Hickie, Gregor Berger, Eric Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Roessler, Swapna Verma, Maximus Berger, Andrew Thompson, Alison YungAlison Yung, Patrick D McGorry
NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS